Compare Innovative Industrial Properties Inc (IIPR) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Organon & Co. Common Stock — how do they compare? Innovative Industrial Properties Inc trades at $51.47 (market cap $1.42B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 2.5× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays the higher dividend (14.74%). Which is the better fit depends on your goals — on Pluang, investors hold Innovative Industrial Properties Inc for 87 Days and Organon & Co. Common Stock for 0 Days on average.
| IIPR | OGN | |
|---|---|---|
Market Cap | $1.42B | $3.62B |
Volume | 427,967 | 2,892,999 |
Sector | Real Estate | Health |
52-Week High | $64.67 | $13.81 |
52-Week Low | $44.58 | $5.70 |
Typical Hold Time | 87 Days | 0 Days |
Enterprise Value | $1.95B | $11.04B |
Dividend Yield | 14.74% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $51.43, up 0.47% on the day, exhibiting a bearish technical trend near key support at $51. Fundamentally, the REIT shows high gross margins of 88.35% but faces revenue and net income declines in 2025. Recent news highlights a significant $245 million mezzanine loan commitment, signaling active capital deployment despite sector headwinds.
The outlook is mixed; the stock offers a high dividend yield but carries risks from tenant defaults and volatile earnings. Analyst consensus is cautious with a majority Hold rating. Investors should weigh the attractive valuation metrics against operational challenges in the cannabis real estate sector.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
